Finally, Fobare et al., in their analysis on 1725 newly diagnosed AML patients, including 140 PTPN11-mut AML patients treated with intensive induction chemotherapy, showed that PTPN11 mutations did not affect the outcomes of NPM1-mut patients, but had an adverse effect on NPM1-WT patients [89]. The gene discussed is NPM1; the disease is acute myeloid leukemia.